Malignant pheochromocytoma: A review

American Journal of Surgery

Volumn 201, Issue 5, 2011, Pages 700-708

  Harari, Avital ^a   Inabnet III, William B ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Endocrinology; Malignant; Oncology; Paraganglioma; Pheochromocytoma; Review

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ADRENERGIC RECEPTOR BLOCKING AGENT; ANTHRACYCLINE; CALCIUM CHANNEL BLOCKING AGENT; CATECHOLAMINE; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; DACARBAZINE; DOPAMINE; HEAT SHOCK PROTEIN 90; KI 67 ANTIGEN; METADRENALIN; NUCLEOSIDE DIPHOSPHATE KINASE NM23; RNA; SECRETOGRANIN II; SUCCINATE DEHYDROGENASE; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; THIOREDOXIN INTERACTING PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 4; VANILMANDELIC ACID; VINCRISTINE;

ADRENALECTOMY; ALPHA ADRENERGIC RECEPTOR BLOCKING; ANXIETY; APOPTOSIS; ARTIFICIAL EMBOLISM; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CATECHOLAMINE BLOOD LEVEL; CATECHOLAMINE URINE LEVEL; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; CRYOABLATION; CYBERKNIFE; CYTOREDUCTIVE SURGERY; DIAPHORESIS; DIFFUSION WEIGHTED IMAGING; DOPAMINE BLOOD LEVEL; FLUID RESUSCITATION; FLUSHING; FOLLOW UP; GAMMA KNIFE RADIOSURGERY; GENE MUTATION; HEADACHE; HEART PALPITATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIQUID CHROMATOGRAPHY; LYMPHADENECTOMY; MEDLINE; MITOSIS RATE; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIOFREQUENCY ABLATION; RADIOIMMUNOASSAY; REVIEW; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; SYNCOPE; TANDEM MASS SPECTROMETRY; THORAX PAIN; TUMOR DIFFERENTIATION; TUMOR NECROSIS; TUMOR RECURRENCE; TUMOR REGRESSION; VEIN BYPASS; WEAKNESS; WEIGHT REDUCTION;

EID: 79955678783     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2010.04.012     Document Type: Review

References (49)

1. Portela-Gomes GM, Stridsberg M, Grimelius L, et al. Expression of chromogranins A, B, and C (secretogranin II) in human adrenal medulla and in benign and malignant pheochromocytomas. An immuno-histochemical study with region-specific antibodies. APMIS 2004;112:663-73.
2. Allibhai Z, Rodrigues G, Brecevic E, et al. Malignant pheochromocytoma associated with germline mutation of the SDHB Gene. J Urol 2004;172:1409-10. (Pubitemid 39249731)
3. De Toma G, Letizia C, Cavallaro G, et al. Malignant pheochromocytoma. Personal experience and review of the literature. Ann Ital Chir 2002;73:413-8.
4. Thompson LD. Pheochromocytoma of the adrenal Gland scaled score (PASS) to separate benign from malignant neoplasms. A Clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 2002;26:551-66. (Pubitemid 34438716)
5. Brunt L, Moley J. Diseases of the adrenal medulla. In: Townsend C, Beauchamp R, Evers B, et al, eds. Sabiston Textbook of Surgery. Philadelphia, PA: Elsevier; 2004:1052-6.
6. Tang SH, Chen A, Lee CT, et al. Remote recurrence of malignant pheochromocytoma 14 years after primary operation. J Urol 2003;169:269. (Pubitemid 35461606)
7. Edstrom Elder E, Hjelm Skog AL, Hoog A, et al. The management of benign and malignant pheochromocytoma and abdominal paraganglioma. Eur J Surg Oncol 2003;29:278-83. (Pubitemid 36395565)
8. Nakane M, Takahashi S, Sekine I, et al. Successful treatment of malignant pheochromocytoma with combination chemotherapy containing anthracycline. Ann Oncol 2003;14:1449-51.
9. Strong VE, Kennedy T, Al-Ahmadie H, et al. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. Surgery 2008;143:759-68.
10. Scholz T, Eisenhofer G, Pacak K, et al. Clinical review: current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab 2007;92:1217-25. (Pubitemid 46556388)
11. Tanaka S, Ito T, Tomoda J, et al. Malignant pheochromocytoma with hepatic metastasis diagnosed 20 years after resection of the primary adrenal lesion. Intern Med 1993;32:789-94.
12. Ohta S, Lai EW, Pang AL, et al. Downregulation of metastasis suppressor genes in malignant pheochromocytoma. Int J Cancer 2005;114:139-43. (Pubitemid 40194319)
13. Ahlman H. Malignant pheochromocytoma: state of the field with future projections. Ann N Y Acad Sci 2006;1073:449-64. (Pubitemid 44912040)
14. Eisenhofer G, Bornstein SR, Brouwers FM, et al. Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer 2004;11:423-36. (Pubitemid 39331275)
15. Scholz T, Schulz C, Klose S, et al. Diagnostic management of benign and malignant pheochromocytoma. Exp Clin Endocrinol Diabetes 2007;115:155-9. (Pubitemid 46640281)
16. Chrisoulidou A, Kaltsas G, Ilias I, et al. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer 2007;14:569-85. (Pubitemid 350074048)
17. Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 2002;287:1427-34.
18. Bravo EL, Tarazi RC, Fouad FM, et al. clonidine-suppression test: a useful aid in the diagnosis of pheochromocytoma. N Engl J Med 1981;305:623-6. (Pubitemid 12201116)
19. Rao F, Keiser HR, O'Connor DT. Malignant pheochromocytoma: chromaffin granule transmitters and response to treatment. Hypertension 2000;36:1045-52.
20. Brouwers FM, Elkahloun AG, Munson PJ, et al. Gene expression profiling of benign and malignant pheochromocytoma. Ann N Y Acad Sci 2006;1073:541-56. (Pubitemid 44912049)
21. Gimenez-Roqueplo AP, Favier J, Rustin P, et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. COMETE Network. Cancer Res 2004;63:5615-21.
22. Brown HM, Komorowski RA, Wilson SD, et al. Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation: A positive correlation between MIB-1 staining and malignant tumor behavior. Cancer 1999;86:1583-9. (Pubitemid 29489795)
23. John H, Ziegler WH, Hauri D, et al. Pheochromocytomas: can malignant potential be predicted? Urology 1999;53:679-83.
24. Boltze C, Mundschenk J, Unger N, et al. Expression profile of the telomeric complex discriminates between benign and malignant pheochromocytoma. J Clin Endocrinol Metab 2003;88:4280-6. (Pubitemid 37153732)
25. Kubota Y, Nakada T, Sasagawa I, et al. Elevated levels of telomerase activity in malignant pheochromocytoma. Cancer 1998;82:176-9. (Pubitemid 28070495)
26. Liu TH, Chen YJ, Wu SF, et al. Distinction between benign and malignant pheochromocytomas. Zhonghua Bing Li Xue Za Zhi 2004;33:198-202.
27. Bigbee W, Herberman RB. Tumor Markers and immunodiagnosis. In: Kufe DW, Pollock RE; Weichselbaum RR, et al. eds. Cancer Medicine. 6th edn. Hamilton, Ontario: BC Decker; 2003:6;211.
28. Koch CA, Vortmeyer AO, Diallo R, et al. Survivin: a novel neuroendocrine marker for pheochromocytoma. Eur J Endocrinol 2002; 146:381-8. (Pubitemid 34257649)
29. Pan L, Peng XC, Leng F, et al. Therapeutic effects of survivin dominant negative mutant in a mouse model of prostate cancer. J Cancer Res Clin Oncol 2010. [Epub ahead of print].
30. Takano A, Oriuchi N, Tsushima Y, et al. Detection of metastatic lesions from malignant pheochromocytoma and paraganglioma with diffusion-weighted magnetic resonance imaging: comparison with 18F-FDG positron emission tomography and 123I-MIBG scintigraphy. Ann Nucl Med 2008;22:395-401. (Pubitemid 351938512)
31. Shapiro B, Gross MD, Shulkin B. Radioisotope diagnosis and therapy of malignant pheochromocytoma. Trends Endocrinol Metab 2001;12:469-75. (Pubitemid 33714249)
32. Ezuddin S, Fragkaki C. MIBG and FDG PET findings in a patient with malignant pheochromocytoma: a significant discrepancy. Clin Nucl Med 2005;30:579-81. (Pubitemid 41026211)
33. Kann PH, Wirkus B, Behr T, et al. Endosonographic imaging of benign and malignant pheochromocytomas. J Clin Endocrinol Metab 2004;89:1694-7. (Pubitemid 38507921)
34. Rabii R, Cicco A, Salomon L, et al. Laparoscopic excision of paraaortic lymphatic metastases of malignant pheochromocytoma. Ann Urol (Paris) 2001;35:81-3. (Pubitemid 32304162)
35. Waidelich R, Weninger E, Denzlinger C, et al. Use of veno-venous bypass for resection of malignant pheochromocytoma with vena caval thrombus. Int Urol Nephrol 2002;34:241-3. (Pubitemid 36559630)
36. Naoi Y, Tamaki Y, Ooka M, et al. A case of metastatic pheochromocytoma with remarkable response to combination of cyclophosphamide, vincristine, and dacarbazine. Gan To Kagaku Ryoho 2003;30:145-9.
37. Huang H, Abraham J, Hung E, et al. Treatment of malignant pheochromocytoma/ paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer 2008;113:2020-28.
38. Tato A, Orte L, Diz P, et al. Malignant pheochromocytoma, still a therapeutic challenge. Am J Hypertens 1997;10:479-81. (Pubitemid 27195987)
39. Watanabe D, Tanabe A, Naruse M, et al. Transcatheter arterial embolization for the treatment of liver metastases in a patient with malignant pheochromocytoma. Endocr J 2006;53:59-66.
40. Takahashi K, Ashizawa N, Minami T, et al. Malignant pheochromocytoma with multiple hepatic metastases treated by chemotherapy and transcatheter arterial embolization. Intern Med 1999;38:349-54. (Pubitemid 29254585)
41. Fassnacht M, Kreissl MC, Weismann D, et al. New targets and therapeutic approaches for endocrine malignancies. Pharmacol Ther 2009;123:117-41.
42. Safford SD, Coleman RE, Gockerman JP, et al. Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery 2003;134:956-62.
43. Sisson JC, Shulkin BL, Esfandiari NH. Courses of malignant pheochromocytoma: implications for therapy. Ann N Y Acad Sci 2006;1073:505-11. (Pubitemid 44912044)
44. Fitzgerald PA, Goldsby RE, Huberty JP, et al. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). Ann N Y Acad Sci 2006;1073:465-90.
45. Nakabeppu Y, Nakajo M. Radionuclide therapy of malignant pheochromocytoma with 131I-MIBG. Ann Nucl Med 1994;8:259-68. (Pubitemid 24374356)
46. Sakahara H, Endo K, Saga T, et al. 131I-metaiodobenzylguanidine therapy for malignant pheochromocytoma. Ann Nucl Med 1994;8:133-7.
47. Kolby L, Bernhardt P, Johanson V, et al. Can quantification of VMAT and sstr expression be helpful for planning radionuclide therapy of malignant pheochromocytomas? Ann N Y Acad Sci 2006;1073:491-7.
48. Adler JT, Meyer-Rochow GY, Chen H, et al. Pheochromocytoma: current approaches and future directions. Oncologist 2008;13:779-93.
49. Morikawa T, Suzuki M, Unno M, et al. Malignant pheochromocytoma with hepatic metastasis diagnosed 10 years after a resection of the primary incidentaloma adrenal lesion: report of a case. Surg Today 2001;31:80-4. (Pubitemid 32200350)